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To the editor - High-income countries’ (HIC) COVID-19 vaccination programs have 
benefited from their ability to secure contracts for preferential supply for several 
vaccines.1 For the rest of the world, vaccine access is much less certain. While G20 
leaders have pledged to ensure fair distribution of COVID-19 vaccines worldwide, 
substantial challenges remain. The COVAX Facility aims to ensure all countries will 
have equal access and competes with high-income countries to acquire doses, but 
some low-income countries (LIC) may need to wait until at least next year before even 
the most vulnerable 20% of their populations are vaccinated.2 
There are increasing calls for HIC to donate a proportion of their vaccine doses. In the 
H1N1 pandemic there was a co-ordinated effort among HIC to make a vaccine to 
protect the world’s poorest, including a pledge by President Obama to donate 10% of 
the United States’ vaccine supply; this was supported by the general public.3 
A key factor that could shape the willingness of governments to make COVID-19 
vaccines available to LICs is their public’s willingness to support donations. We 
provide evidence on this issue with an international internet-based survey4 that was 
conducted between 24 Nov and 28 Dec 2020. The overall study involved 15,536 
individuals from 13 countries who completed an anonymous survey using Qualtrics 
web-based software. Quota sampling (and in five countries additional weighting) was 
used to obtain a sample that reflected the distribution of age, education, gender and 
region in each country.  
We obtained information from 8,209 adult individuals from a subset of seven high-
income countries (Australia, Canada, France, Italy, Spain, UK, US). The survey used 
a Visual Analogue Scale to measure agreement (from 0: ‘very much disagree’ to 100: 
‘very much agree’) with three prioritization principles for the global allocation of 
COVID-19 treatments and vaccines. We asked if these should be first provided for: (i) 
“those who need them most”; (ii) “those who cannot afford to buy them”; (iii) “those 
who live in the country in which they are first developed”. Secondly, we adapted a 
question previously used in the context of H1N13 and asked whether respondents 
supported donating some COVID-19 vaccine doses for distribution to poor countries 
with insufficient resources to buy their own vaccines. Those willing to donate indicated 
whether they favoured an amount greater than, equal to, or less than 10% of their 
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country’s doses. Proportions and means, including 95% CIs, are reported, and the 
data used to estimate these statistics are available from the authors upon request. 
Regarding the global allocation criteria for vaccines, the highest average level of 
agreement is based on need (with average agreement ranging from 70 (95% CI 68-
71) to 80 (95% CI 78-81); then affordability (62 (95% CI 60-64) to 70 (95% CI 68-71)); 
and finally whether the country developed the vaccine (28 (95% CI 26-29) to 58 (95% 
CI 56-60)). This ranking is consistent across all countries. Table 1 shows the opinions 
regarding donation of purchased vaccines. The proportions supporting donation were 
more than double the proportions who did not support donating.  
While current supplies are limited, many HIC have pre-purchased supplies exceeding 
their population size. For example, the US has reserved more than 1.2 billion doses5 
and Canada has premarket commitments covering more than nine doses per person.1 
Redistributing some of these supplies would have global benefits. It would reduce the 
risk of the emergence and spread of new variants and, according to predictions, 
benefit the economy, both globally and in donor countries.6 In contrast, the economic 
cost of vaccine nationalism (where a few countries push to gain preferential access) 
is potentially high, with a recent report suggesting it could cost up to $1.2 trillion per 
year to the world’s economy.7  
While we did not investigate opinions regarding the timing of donations, national 
vaccination strategies should be taking into account these broader benefits. Notably, 
countries such as Norway8 have already pledged to distribute vaccines at the same 
time as vaccinating their own populations. Such policies are likely to maximize global 
health benefits. A recent modelling study suggests that allocating doses internationally 
in proportion to countries' population sizes would be a close to optimal strategy in 
terms of averting deaths.9 
Like prevalence studies, these opinions represent a single point in time but, 
importantly, our survey was conducted at a time when the distribution of COVID-19 
vaccines was no longer a hypothetical question. More broadly, understanding and 
potentially influencing public opinion will be important components of any strategies to 
combat COVID-19 and prevent future pandemics.10 This global problem requires 
global solutions and our survey indicates that redistribution of some pre-purchased 





Table 1 Preferences of public regarding donation of vaccines governments has 















 < 10% 10% > 10% Any level* 
Australia 10 (8 12) 21 (18 23) 20 (18 22) 51 (48 54) 20 (17 22) 27 (24 29) 3 (2 4) 
Canada 15 (13 17) 26 (23 28) 15 (13 18) 56 (53 59) 20 (18 23) 22 (19 24) 2 (1 3) 
France 11 (9 13) 16 (14 19) 21 (18 23) 48 (45 51) 20 (17 22) 28 (25 31) 4 (3 5) 
Italy 13 (11 15) 19 (16 21) 22 (19 25) 54 (50 57) 15 (13 18) 28 (25 31) 3 (2 4) 
Spain 11 (9 13) 25 (23 28) 18 (16 21) 55 (52 58) 15 (13 17) 23 (21 26) 7 (5 8) 
United 
Kingdom 
14 (12 16) 21 (19 24) 16 (13 18) 51 (48 54) 26 (23 29) 22 (19 24) 1 (1 2) 
United 
States 
10 (8 12) 19 (16 22) 22 (20 25) 52 (48 55) 17 (15 20) 25 (22 28) 6 (4 8) 
Notes: *Any level combines responses from <10%, 10% and >10% categories; Based on 
data from CANDOUR study, for details see https://oxford-candour.com/; Sample sizes:  
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